LinkedIn Profile

Access CrystalGenomics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
private:crystalgenomics 1537759 May 23rd, 2019 12:00AM CrystalGenomics, Inc. 165 20.00 Open Biotechnology May 23rd, 2019 07:08PM May 23rd, 2019 07:08PM CrystalGenomics is a commercial stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for global development in California, and it is publicly traded on the KOSDAQ exchange (083790). CrystalGenomics has a product on the market and is developing several novel drug candidates in different therapeutic areas. The marketed product is Acelex® (polmacoxib), a next generation NSAID for the treatment of signs and symptoms of osteoarthritis. The first clinical stage program is CG-745, an epigenetic agent applicable to various types of solid and liquid tumors and currently, phase 2 clinical trials are ongoing for pancreatic cancer and MDS. The second clinical stage program is CG-549, a novel class antibiotic for MRSA where its phase 2a skin infection study in the US had been completed with a positive outcome of 100% clinical cure rate. The Company's therapeutic candidates are discovered and developed through its proprietary discovery platform technology which utilizes the integrated technologies of the SPS™ (technology for structure determination), the SCP™ (technology for the generation of lead compounds) and the SDF™(technology used for lead optimization) technologies. By leveraging its capabilities and the know-how in novel drug discovery and development, CrystalGenomics will continue to strive in making significant contributions for improving human health. For more information, please visit: www.cgxinc.com or www.crystalgenomics.com. Open Open CrystalGenomics, Inc., 5F Tower A, Korea Bio Park, 694-1, Sampyeong-Dong, Bundang-Gu Seongnam-Si Gyeonggi-Do KR 463-400 Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 17th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 16th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 15th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 14th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 13th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 12th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 11th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 10th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services
private:crystalgenomics 1537759 Feb 9th, 2018 12:00AM CrystalGenomics, Inc. 131 23.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM CrystalGenomics Inc. is a clinical stage biopharmaceutical company that is dedicated to the discovery and development of novel pharmaceuticals with innovative platform technologies to address significant unmet medical needs in the areas of infectious disease, oncology, and inflammatory diseases. The Company is headquartered in Korea and has a US presence for multi-national clinical development in Emeryville, California, and it is publicly traded on the KOSDAQ exchange. Our mission is to provide patients with highest quality products through innovations that will improve patients’ quality of life. We commit ourselves to high standards of integrity in contributing to the best interests of patients, our employees and our communities, and to pursue maximum returns for our shareholders. The Company’s lead therapeutic program is CG100649, a next generation NSAID in phase 3 for osteoarthritis and it also has a first-in-class antibiotic for MRSA in phase 2 (CG400549) as well as a molecular targeted cancer therapeutic for solid tumors in phase 1 development (CG200745). Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.